Cantor Fitzgerald Reiterates Overweight Rating on Metsera Inc (MTSR)

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Metsera Inc (NASDAQ: MTSR).

The analyst commented, "This past week, we hosted the Metsera team for virtual meetings with EU investors. In the note, we also outline initial thoughts on the upcoming P1 readout in 2Q25 for injectable amylin analog (MET-233i). There is growing appreciation for Metsera's pipeline differentiation and breadth, with options to cater to different segments of the obesity market. Scalability advantages (e.g.,, low CapEx requirements) are also key. An attractive catalyst path in the next 6-9 months should derisk injectable amylin and oral peptides."

For an analyst ratings summary and ratings history on Metsera Inc click here. For more ratings news on Metsera Inc click here.

Shares of Metsera Inc closed at $27.30 yesterday.

You May Also Be Interested In

• Kodiak Gas Services, Inc. (KGS) Reports Q2 EPS of $0.55
• Tectonic Therapeutic (TECX) Tops Q2 EPS by 17c
• iRhythm Technologies (IRTC) Tops Q2 EPS by 63c; Offers Guidance